142 related articles for article (PubMed ID: 17991538)
1. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.
Carter HB; Kettermann A; Ferrucci L; Landis P; Metter EJ
Urology; 2007 Oct; 70(4):685-90. PubMed ID: 17991538
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.
Loeb S; Metter EJ; Kan D; Roehl KA; Catalona WJ
BJU Int; 2012 Feb; 109(4):508-13; discussion 513-4. PubMed ID: 22296334
[TBL] [Abstract][Full Text] [Related]
3. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
Carter HB; Ferrucci L; Kettermann A; Landis P; Wright EJ; Epstein JI; Trock BJ; Metter EJ
J Natl Cancer Inst; 2006 Nov; 98(21):1521-7. PubMed ID: 17077354
[TBL] [Abstract][Full Text] [Related]
4. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.
Fang J; Metter EJ; Landis P; Carter HB
Urology; 2002 Jun; 59(6):889-93; discussion 893-4. PubMed ID: 12031375
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
6. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality.
Nguyen PL; Chen MH; Renshaw AA; Sussman B; D'Amico AV
Urology; 2007 Aug; 70(2):288-93. PubMed ID: 17826491
[TBL] [Abstract][Full Text] [Related]
7. Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality.
Ørsted DD; Bojesen SE; Kamstrup PR; Nordestgaard BG
Eur Urol; 2013 Sep; 64(3):384-93. PubMed ID: 23398767
[TBL] [Abstract][Full Text] [Related]
8. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
O'Brien MF; Cronin AM; Fearn PA; Savage CJ; Smith B; Stasi J; Scardino PT; Fisher G; Cuzick J; Møller H; Oliver RT; Berney DM; Foster CS; Eastham JA; Vickers AJ; Lilja H;
Int J Cancer; 2011 May; 128(10):2373-81. PubMed ID: 20658531
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
[TBL] [Abstract][Full Text] [Related]
11. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.
King CR; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
Urology; 2007 Apr; 69(4):732-7. PubMed ID: 17445660
[TBL] [Abstract][Full Text] [Related]
12. Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging.
Loeb S; Carter HB; Schaeffer EM; Kettermann A; Ferrucci L; Metter EJ
Urology; 2011 Jan; 77(1):143-7. PubMed ID: 21195835
[TBL] [Abstract][Full Text] [Related]
13. Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.
Kettermann AE; Ferrucci L; Trock BJ; Metter EJ; Loeb S; Carter HB
BJU Int; 2010 Nov; 106(9):1284-90; discussion 1290-2. PubMed ID: 20477823
[TBL] [Abstract][Full Text] [Related]
14. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program.
Eggener SE; Yossepowitch O; Roehl KA; Loeb S; Yu X; Catalona WJ
Urology; 2008 Jun; 71(6):1016-9. PubMed ID: 18358515
[TBL] [Abstract][Full Text] [Related]
15. Significance of preoperative PSA velocity in men with low serum PSA and normal DRE.
Makarov DV; Loeb S; Magheli A; Zhao K; Humphreys E; Gonzalgo ML; Partin AW; Han M
World J Urol; 2011 Feb; 29(1):11-4. PubMed ID: 21153643
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone.
Rossi PJ; Urbanic J; Clark PE; McCullough DL; Lee WR
Brachytherapy; 2008; 7(4):286-9. PubMed ID: 18928924
[TBL] [Abstract][Full Text] [Related]
17. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging.
Loeb S; Kettermann A; Ferrucci L; Landis P; Metter EJ; Carter HB
Eur Urol; 2008 Nov; 54(5):1073-80. PubMed ID: 18614274
[TBL] [Abstract][Full Text] [Related]
18. The role of prostate-specific antigen velocity in prostate cancer early detection.
Potter SR; Carter HB
Curr Urol Rep; 2000 May; 1(1):15-9. PubMed ID: 12084336
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
20. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC
Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
